Skip to main content
Premium Trial:

Request an Annual Quote

Biofortuna to Use TriLink dNTPs in Diagnostic PCR Kits


TriLink BioTechnologies said this week that it has signed a licensing agreement with Biofortuna for use of its CleanAmp dNTPs in Biofortuna's freeze-dried in vitro diagnostic PCR kits.

Biofortuna will use the dNTPs for a line of human leukocyte antigen diagnostic kits it is developing for the transplantation, blood grouping, disease identification, and pharmacogenetic markets. The company is targeting its first product for the sequence-specific primer transplantation market.

TriLink said that Biofortuna was able to improve the specificity of its genotyping assays by replacing standard dNTPs with CleanAmp dNTPs.